Besremi 500 mcg/mL prefilled syringe Images
Generic Name: ropeginterferon alfa-2b
This medication has been identified as Besremi 500 mcg/mL prefilled syringe. It is supplied by PharmaEssentia USA.
Besremi is used in the treatment of Polycythemia Vera and belongs to the drug class antineoplastic interferons. Besremi 500 mcg/mL prefilled syringe is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Besremi
- Generic Name
- ropeginterferon alfa-2b
- Strength
- 500 mcg/mL prefilled syringe
- Availability
- Prescription only
- Drug Class
- Antineoplastic interferons
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- PharmaEssentia USA
- National Drug Code (NDC)
- 73536-0500
See also:
Jakafi
Jakafi is used to treat certain types of myelofibrosis or polycythemia vera in adults, and certain ...
Intron A
Intron A is used for angioblastoma, condylomata acuminata, conjunctival mucosa-associated lymphoid ...
Caplyta
Caplyta is used to treat schizophrenia or depression associated with bipolar disorder. It is taken ...
PegIntron
PegIntron is used to treat chronic hepatitis C in adults. Learn about side effects, interactions ...
Sylatron
Sylatron (peginterferon alfa-2b) used to prevent malignant melanoma from coming back after it has ...
Ropeginterferon alfa-2b
Ropeginterferon alfa-2b is used for polycythemia vera
Peginterferon alfa-2b
Peginterferon alfa-2b is used for chronic myelogenous leukemia, hepatitis b, hepatitis c, melanoma ...
Interferon alfa-2b
Interferon alfa-2b is used for angioblastoma, condylomata acuminata, conjunctival mucosa-associated ...
Ruxolitinib
Ruxolitinib (oral) is used to treat certain types of myelofibrosis (MF), polycythemia vera (PV) ...
More about Besremi (ropeginterferon alfa-2b)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: antineoplastic interferons
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.